Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Crosses Below 200-Day Moving Average – What’s Next?

by · The Markets Daily

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $67.83 and traded as low as $66.85. Tarsus Pharmaceuticals shares last traded at $67.52, with a volume of 1,715,283 shares.

Key Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

  • Positive Sentiment: Recent coverage highlights record Q3 sales and a raised revenue outlook, supporting the view that commercial momentum is improving. The reported $194.57 million in quarterly revenue also exceeded the cited consensus estimate of $187.83 million. Tarsus Pharmaceuticals Could Be 31% Undervalued Following Record Q3 Sales
  • Positive Sentiment: Guggenheim raised its price target to $97 from $89 and maintained a Buy rating. HC Wainwright also kept its Buy rating and $106 target, while raising its FY2027–FY2030 earnings forecasts, suggesting greater confidence in longer-term profitability. Tarsus Pharmaceuticals Stock Gets Price Target Increase from HC Wainwright
  • Neutral Sentiment: Tarsus plans to participate in upcoming investor conferences. The announcement may provide opportunities for investor updates but does not disclose a new business or clinical development. Tarsus to Participate in Upcoming Investor Conferences
  • Negative Sentiment: HC Wainwright cut its Q4 2026 EPS forecast to a loss of $0.55 from a loss of $0.14, and reduced its FY2026 estimate to a loss of $15.85 from $2.25. Separately, Tarsus reported a Q3 loss of $14.40 per share, substantially wider than the cited $1.46 consensus loss. These figures raise concern about near-term costs and profitability despite revenue growth.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on TARS shares. Oppenheimer raised their target price on shares of Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. Jefferies Financial Group lifted their price objective on shares of Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, September 8th. Mizuho decreased their price objective on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. The Goldman Sachs Group assumed coverage on shares of Tarsus Pharmaceuticals in a research report on Thursday, September 24th. They issued a “buy” rating and a $116.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $104.57.

Read Our Latest Stock Report on Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Price Performance

The company has a 50 day moving average of $74.99 and a 200-day moving average of $67.82. The firm has a market capitalization of $3.38 billion, a P/E ratio of -4.52 and a beta of 0.34. The company has a current ratio of 3.20, a quick ratio of 3.17 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($14.40) earnings per share for the quarter, missing the consensus estimate of ($1.46) by ($12.94). Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%. The firm had revenue of $194.57 million for the quarter, compared to the consensus estimate of $187.83 million. On average, sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -12.10 EPS for the current year.

Insider Activity at Tarsus Pharmaceuticals

In related news, insider Elizabeth Lin sold 10,773 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $87.50, for a total transaction of $942,637.50. Following the transaction, the insider directly owned 2,547 shares of the company’s stock, valued at approximately $222,862.50. This trade represents a 80.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Bobak Azamian sold 10,000 shares of Tarsus Pharmaceuticals stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $90.56, for a total transaction of $905,600.00. Following the completion of the sale, the chief executive officer owned 827,991 shares of the company’s stock, valued at $74,982,864.96. This trade represents a 1.19% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 48,031 shares of company stock worth $4,004,227. Corporate insiders own 9.64% of the company’s stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in TARS. Parallel Advisors LLC boosted its stake in shares of Tarsus Pharmaceuticals by 139.2% in the first quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock valued at $35,000 after buying an additional 291 shares during the period. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Tarsus Pharmaceuticals during the 3rd quarter worth $35,000. Farther Finance Advisors LLC grew its holdings in shares of Tarsus Pharmaceuticals by 851.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 590 shares of the company’s stock worth $46,000 after purchasing an additional 528 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Tarsus Pharmaceuticals by 367.1% in the first quarter. PNC Financial Services Group Inc. now owns 710 shares of the company’s stock worth $50,000 after purchasing an additional 558 shares during the period. Finally, Covestor Ltd increased its position in shares of Tarsus Pharmaceuticals by 40.0% in the third quarter. Covestor Ltd now owns 1,095 shares of the company’s stock worth $86,000 after purchasing an additional 313 shares during the period. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Company Profile

(Get Free Report)

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye diseases with significant unmet medical needs. The company’s portfolio is centered on therapies designed to address conditions affecting the ocular surface and eyelids.

Tarsus’ lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, an inflammatory eyelid condition associated with an infestation of Demodex mites.

Further Reading